#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

#### INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3)

## AC IMMUNE SA (Name of Issuer)

Common shares, nominal value CHF 0.02 per share (Title of Class of Securities)

#### H00263105 (CUSIP Number)

#### December 31, 2020 (Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 $\square$  Rule 13d-1(b)

 $\square$  Rule 13d-1(c)

⊠ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

13 G

Page 2 of 14 Pages

1	Nome of Dana	rtin a D					
1.	Name of Reporting Persons						
	dievini Hopp	BioTec	h holding GmbH & Co. KG				
2.			e Box if a Member of a Group (See Instructions)				
3.	SEC USE ONI	LY					
4.	Citizenship or	Place o	f Organization				
	Germany						
		5.	Sole Voting Power				
			0 common shares				
	ber of	6.	Shared Voting Power				
	ares icially	0.	Shared voting rower				
	ed by		18,041,000 common shares <sup>(2)</sup>				
Ea	ich	7.	Sole Dispositive Power				
	orting rson						
	ith:	8.	0 common shares Shared Dispositive Power				
		0.	Shared Dispositive Power				
			18,041,000 common shares <sup>(2)</sup>				
9.	Aggregate Am	ount B	eneficially Owned by Each Reporting Person				
	18,041,000 coi		1 (2)				
10.			The Amount in Row (9) Excludes Certain Shares (See Instructions)				
10.	Check if the A	ggrega	e Amount in Row (9) Excludes Certain Shares (See instructions)				
11.	Percent of Clas	ss Repr	esented by Amount in Row (9)				
	25.1% <sup>(3)</sup>						
12.		ting De	rson (See Instructions)				
12.	Type of Repor	ung i ci					
	00						

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

(2) Represents shares held of record by dievini.

13 G

Page 3 of 14 Pages

1.	Name of Re	porting Po	ersons			
	DII Carita	I Carl				
2.	<b>DH-Capita</b> Check the A		e Box if a Member of a Group (See Instructions)			
		(b) 🗆 <sup>(1)</sup>				
3.	SEC USE C	ONLY				
4.	. Citizenship or Place of Organization					
	Germany					
		5.	Sole Voting Power			
	1		0 common shares			
	ber of	6.	Shared Voting Power			
	ficially					
	ed by	7.	18,041,000 common shares <sup>(2)</sup> Sole Dispositive Power			
	orting	7.	Sole Dispositive I ower			
-	rson ith:		0 common shares			
vv	1011.	8.	Shared Dispositive Power			
			18,041,000 common shares <sup>(2)</sup>			
9.	Aggregate A	Amount B	eneficially Owned by Each Reporting Person			
	18,041,000	common s	shares <sup>(2)</sup>			
10.			te Amount in Row (9) Excludes Certain Shares (See Instructions)			
11.	Doroont of (	lass Dopr	resented by Amount in Row (9)			
11.		lass repi	esented by Amount in Row (7)			
	25.1% <sup>(3)</sup>					
12.	Type of Rep	oorting Pe	rson (See Instructions)			
	00					

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

(2) Represents shares held of record by dievini.

13 G

Page 4 of 14 Pages

1	N CD (						
1.	Name of Reporting Persons						
	OH Beteiligung	mbH & Co. KG					
2.	Check the Appropriate Box if a Member of a Group (See Instructions)						
	(a) 🗌 (b) 🗆						
3.	SEC USE ONLY						
4.	Citizenship or Pl	of Organization					
	Germany						
	5	Sole Voting Power					
		0 common shares					
	ber of	Shared Voting Power					
	ares ( icially	Shared voting I ower					
	ed by	18,041,000 common shares <sup>(2)</sup>					
Ea	ich	Sole Dispositive Power					
	orting						
-	rson ith: 8	0 common shares					
***		Shared Dispositive Power					
		18,041,000 common shares <sup>(2)</sup>					
9.	Aggregate Amou	eneficially Owned by Each Reporting Person					
	10.041.000	. (2)					
10.	18,041,000 com	te Amount in Row (9) Excludes Certain Shares (See Instructions)					
10.	Check II the Age	e Amount in Row (9) Excludes certain Shares (see instructions)					
11.	Percent of Class	resented by Amount in Row (9)					
	2 - (2)						
12	25.1% <sup>(3)</sup>	(Cas Instructions)					
12.	Type of Keportin	rson (See Instructions)					
	00						

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

(2) Represents shares held of record by dievini.

Page 5 of 14 Pages

1.	Name of R	eporting Po	ersons				
	Dietmar H	onn					
2.	Check the Appropriate Box if a Member of a Group (See Instructions)						
3.	(a) SEC USE (	$\frac{(b) \square^{(1)}}{ONLY}$					
4.	Citizenship	or Place o	of Organization				
	Germany						
		5.	Sole Voting Power				
Num	ber of		0 common shares				
Sh	ares	6.	Shared Voting Power				
	ficially ned by		18,041,000 common shares <sup>(2)</sup>				
Ea	ach	7.	Sole Dispositive Power				
	orting rson		0 common shares				
W	'ith:	8.	Shared Dispositive Power				
			18,041,000 common shares <sup>(2)</sup>				
9.	Aggregate	Amount B	eneficially Owned by Each Reporting Person				
	10.041.000		. (2)				
10.	18,041,000 Check if th		te Amount in Row (9) Excludes Certain Shares (See Instructions)				
10.							
11.	Percent of	Class Repr	resented by Amount in Row (9)				
	25.1% <sup>(3)</sup>						
12.	Type of Re	porting Per	rson (See Instructions)				
	IN						

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

(2) Represents shares held of record by dievini.

13 G

Page 6 of 14 Pages

1.	Name of R	Reporting Po	ersons				
	Oliver Ho	DD					
2.							
	(a) $\Box$ (b) $\Box$ <sup>(1)</sup>						
3.	SEC USE						
4	Citi analia	DI					
4.	Citizensnij	p or Place c	of Organization				
	Germany						
		5.	Sole Voting Power				
Num	ber of		0 common shares				
	ares	6.	Shared Voting Power				
	ficially ned by		18,041,000 common shares <sup>(2)</sup>				
	ach	7.	Sole Dispositive Power				
	orting rson		0 common shares				
W	/ith:	8.	Shared Dispositive Power				
			18,041,000 common shares <sup>(2)</sup>				
9.	Aggregate	Amount B	eneficially Owned by Each Reporting Person				
	18.041.000	) common s	shares <sup>(2)</sup>				
10.			te Amount in Row (9) Excludes Certain Shares (See Instructions)				
11.	Percent of	Class Repr	resented by Amount in Row (9)				
		Clubb Repl					
	25.1 <sup>(3)</sup>						
12.	Type of Re	eporting Pe	rson (See Instructions)				
	IN						

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

(2) Represents shares held of record by dievini.

13 G

Page 7 of 14 Pages

1.	Name of Re	eporting Po	ersons				
	Daniel Hop	on					
2.							
	(a) $\Box$ (b) $\Box$ <sup>(1)</sup>						
3.	SEC USE C						
4.	Citizonshin	or Diago	f Organization				
4.		of Place C	n Organization				
	Germany						
		5.	Sole Voting Power				
Num	ber of		0 common shares				
. –	ares	6.	Shared Voting Power				
	ficially ned by		18,041,000 common shares <sup>(2)</sup>				
E	ach	7.	Sole Dispositive Power				
	orting rson		0 common shares				
W	/ith:	8.	Shared Dispositive Power				
			18,041,000 common shares <sup>(2)</sup>				
9.	Aggregate	Amount B	eneficially Owned by Each Reporting Person				
	18,041,000		shares(2)				
10.			te Amount in Row (9) Excludes Certain Shares (See Instructions)				
		00 0					
11.	Percent of G	Class Repr	esented by Amount in Row (9)				
	25.1%						
12.	Type of Rep	porting Pe	rson (See Instructions)				
	IN						

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents shares held of record by dievini.
- (3) This percentage is calculated based on 71,741,285 shares of the Issuer's common shares reported to be issued by the Issuer in its Registration Statement on Form F-3 filed with the Securities and Exchange Commission on October 23, 2020.

13 G

Page 8 of 14 Pages

1	N	Demonstration D					
1.	Name of Reporting Persons						
	Prof. Dr.	Friedrich v	on Bohlen und Halbach				
2.			e Box if a Member of a Group (See Instructions)				
	(a) 🗆	(b) □ <sup>(1)</sup>					
3.	SEC USE	ONLY					
4.	Citizenshi	p or Place o	f Organization				
	CTULECHISH	p 01 1 1400 0					
	Germany						
		5.	Sole Voting Power				
	1 0		0 common shares				
	nber of ares	6.	Shared Voting Power				
	eficially						
	ned by		18,041,000 common shares <sup>(2)</sup>				
	lach	7.	Sole Dispositive Power				
	orting		0 common shares				
-	/ith:	8.	Shared Dispositive Power				
		0.	Shared Dispositive I ower				
			18,041,000 common shares <sup>(3)</sup>				
9.	Aggregate	e Amount B	eneficially Owned by Each Reporting Person				
	10.041.00	0					
10.		0 common s	te Amount in Row (9) Excludes Certain Shares (See Instructions)				
10.	Check II t	ne Aggrega	e Amount in Row (9) Excludes Certain Shares (see instructions)				
11.	Percent of	Class Repr	esented by Amount in Row (9)				
	25.1% <sup>(3)</sup>						
12.	Type of R	eporting Per	rson (See Instructions)				
	IN						
1							

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

(2) Represents shares held of record by dievini

13 G

Page 9 of 14 Pages

1.	Name of Re	eporting Po	Persons			
	Prof. Dr. C	'hristof H	lettich			
2.			te Box if a Member of a Group (See Instructions)			
3.	$(a) \square$ SEC USE (	$\frac{(b) \square^{(1)}}{ONLY}$				
4.	Citizenship	or Place c	of Organization			
	Germany					
		5.	Sole Voting Power			
Nurr	nber of		0 common shares			
	ares	6.	Shared Voting Power			
	ficially ned by		18,041,000 common shares <sup>(2)</sup>			
E	ach	7.	Sole Dispositive Power			
	orting rson		0 common shares <sup>(</sup>			
W	/ith:	8.	Shared Dispositive Power			
			18,041,000 common shares			
9.	Aggregate	Amount B	Beneficially Owned by Each Reporting Person			
	18,041,000	common	shares (2)			
10.			te Amount in Row (9) Excludes Certain Shares (See Instructions)			
11	Demonst of	Class Dama	recented by American in Devis (0)			
11.	Percent of C	lass Kepr	resented by Amount in Row (9)			
	25.1% <sup>(3)</sup>					
12.	Type of Rep	porting Pe	erson (See Instructions)			
	IN					

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

(2) Represents shares held of record by dievini.

13 G

Page 10 of 14 Pages

1.	Name of R	Reporting P	Persons
	Dr. Mathi	as Hothun	n
2.	Check the	Appropriat	te Box if a Member of a Group (See Instructions)
	(a) 🗆	(b) □ <sup>(1)</sup>	
3.	SEC USE		
4.	Citizenshii	n or Place (	of Organization
1.			of organization
	Germany		
		5.	Sole Voting Power
Nurr	nber of		0 common shares
	nares	6.	Shared Voting Power
	eficially ned by		18,041,000 common shares
	lach	7.	Sole Dispositive Power
	orting		
	erson /ith:	0	0 common shares
vv	lull.	8.	Shared Dispositive Power
			18,041,000 common shares
9.	Aggregate	Amount B	Beneficially Owned by Each Reporting Person
	18,041,000	) common	shares (2)
10.			te Amount in Row (9) Excludes Certain Shares (See Instructions)
11.	Percent of	Class Repr	resented by Amount in Row (9)
	25.1 <sup>(3)</sup>		
12.		eporting Pe	erson (See Instructions)
	INI		
	IN		

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

(2) Represents shares held of record by dievini.

13 G

Page 11 of 14 Pages

Introductory Note: This Amendment No. 1 to Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH & Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons") in respect of common shares of AC Immune SA.

#### Item 1(a) Name of Issuer:

AC Immune SA

#### Item 1(b) Address of Issuer's principal executive offices:

EPFL Innovation Park Building B 1015 Lausanne Switzerland

#### Items 2(a) Name of Reporting Persons filing:

dievini Hopp BioTech holding GmbH & Co. KG ("dievini") DH-Capital GmbH & Co. KG ("DH-Capital") OH Beteiligungen GmbH & Co. KG ("OH Beteiligungen") Dietmar Hopp Oliver Hopp Daniel Hopp Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen") Prof. Dr. Christof Hettich ("Dr. Hettich") Dr. Mathias Hothum ("Dr. Hothum")

#### Item 2(b) Address or principal business office or, if none, residence:

The address of the principal business office of dievini, Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum is c/o dievini Hopp BioTech holding GmbH & Co. KG, Johann-Jakob-Astor Straße 57, 69190 Walldorf, Germany.

The address of the principal business office of DH-Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG is Opelstraße 28, 68789 St. Leon-Rot, Germany.

The address of the principal business office of Oliver Hopp is Johann-Jakob-Astor-Straße 59, 69190 Walldorf, Germany.

The address of the principal business office of Daniel Hopp is Johann-Jakob-Astor-Straße 57, 69190 Walldorf, Germany.

#### Item 2(c) Citizenship:

Name	Citizenship or Place of Organization
Dievini	Germany
DH-Capital	Germany
OH Beteiligungen	Germany
Dietmar Hopp	Germany
Oliver Hopp	Germany
Daniel Hopp	Germany
Dr. von Bohlen	Germany
Dr. Hettich	Germany
Dr. Hothum	Germany

13 G

#### Item 2(d) Title of class of securities:

Common shares, nominal value CHF 0.02 per share

Item 2(e) CUSIP No.:

H00263105

#### Item 3 If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:

Not applicable.

#### Item 4 Ownership

The following information with respect to the ownership of common shares of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2018.

Reporting Persons	Common Shares Held Directly	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Beneficial Ownership	Percentage of Class <sup>(1)</sup>
dievini Hopp BioTech holding GmbH & Co. KG <sup>(2)</sup>	18,041,000	0	18,041,000	0	18,041,000	18,041,000	25.1%
DH-Capital GmbH & Co. KG <sup>(3)</sup>	0	0	18,041,000	0	18,041,000	18,041,000	25.1%
OH Beteiligungen GmbH & Co. KG <sup>(3)</sup>	0	0	18,041,000	0	18,041,000	18,041,000	25.1%
Dietmar Hopp <sup>(3)(4)</sup>	0	0	18,041,000	0	18,041,000	18,041,000	25.1%
Oliver Hopp <sup>(3)</sup>	0	0	18,041,000	0	18,041,000	18,041,000	25.1%
Daniel Hopp <sup>(3)</sup>	0	0	18,041,000	0	18,041,000	18,041,000	25.1%
Prof. Dr. Friedrich von Bohlen und							
Halbach <sup>(3)(4)</sup>	0	0	18,041,000	0	18,041,000	18,041,000	25.1%
Prof. Dr. Christof Hettich <sup>(3)(4)</sup>	0	0	18,041,000	0	18,041,000	18,041,000	25.1%
Dr. Mathias Hothum <sup>(4)</sup>	0	0	18,041,000	0	18,041,000	18,041,000	25.1%

- (2) 18,041,000 common shares of the Issuer are held of record by dievini.
- (3) DH-Capital, OH Beteiligungen, Dr. von Bohlen and Dr. Hettich are collectively the holders of 100% of the limited partner interest in dievini. DH-Capital and OH Beteiligungen each hold a 40% limited partner interest in dievini and therefore, control the voting and dispositive decisions of dievini together and may be deemed to beneficially own the shares held by dievini. Dietmar Hopp, Oliver Hopp and Daniel Hopp are the ultimate controlling persons of dievini, DH-Capital and OH Beteiligungen, and control the voting and investment decisions of the ultimate parent company of dievini and therefore, may be deemed to beneficially own the shares held by dievini by virtue of their status as controlling persons of dievini.
- (4) The sole general partner of dievini with the authorization to represent is dievini Verwaltungs GmbH; however, 100% of the shares of dievini Verwaltungs GmbH are held by dievini so dievini Verwaltungs GmbH is not considered to have control over dievini. The managing directors of dievini Verwaltungs GmbH are Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum. Voting and dispositive decisions made within dievini Verwaltungs GmbH regarding the securities held by dievini are made by at least two managing directors acting together; however, Dietmar Hopp is entitled to represent dievini Verwaltungs GmbH solely. Therefore, in their capacity as managing directors, Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum share voting and dispositive power over the shares held by dievini, and may be deemed to beneficially own such shares held by dievini; however, each of Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum disclaims beneficial ownership of the shares held by dievini except to the extent of their pecuniary interests therein.

CUSIP NO. H00	1203	105
---------------	------	-----

13 G

#### Item 5 Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  $\Box$ 

#### Item 6 Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not applicable.

Item 8 Identification and Classification of Members of the Group

Not applicable.

Item 9 Notice of Dissolution of Group

Not applicable.

Item 10 Certifications

Not applicable.

13 G

Page 14 of 14 Pages

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 2021

# DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG

- By: dievini Verwaltungs GmbH its General Partner
- By: /s/ Dr. Marc Hauser Name: Dr. Marc Hauser Title: Attorney-in-fact

### DH-CAPITAL GMBH & CO. KG

- By: DH Verwaltungs GmbH its General Partner
- By: /s/ Dr. Marc Hauser Name: Dr. Marc Hauser Title: Attorney-in-fact

#### OH BETEILIGUNGEN GMBH & CO. KG

- By: OH Verwaltungs GmbH its General Partner
- By: /s/ Dr. Marc Hauser Name: Dr. Marc Hauser Title: Attorney-in-fact

# /s/ Dr. Marc Hauser as attorney-in-fact **DIETMAR HOPP**

/s/ Dr. Marc Hauser as attorney-in-fact
OLIVER HOPP

/s/ Dr. Marc Hauser as attorney-in-fact **DANIEL HOPP** 

/s/ Dr. Marc Hauser as attorney-in-fact FRIEDRICH VON BOHLEN UND HALBACH

/s/ Dr. Marc Hauser as attorney-in-fact CHRISTOF HETTICH

/s/ Dr. Marc Hauser as attorney-in-fact MATHIAS HOTHUM

Exhibit(s):

 1 – Power of Attorney
 Incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons on February 14, 2017 with respect to the common shares of the Issuer.

 2 - Joint Filing Statement
 Incorporated by reference to Exhibit 99.2 to the Schedule 13G filed by the Reporting Persons on February 14, 2017 with respect to the common shares of the Issuer.